EXG102-031

· Guangzhou Jiayin Biotech Ltd

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for EXG102-031, covering 2024-01-09 to 2026-04-08. Get the full timeline:

Most recent: Clinical Trial Update: A Study of EXG102-031 in Patients With wAMD (Everest) [Phase 1]